Last updated 33 days ago

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

620 patients around the world
Available in Brazil
AstraZeneca
620Patients around the world
This study is for people with
Bile Duct Cancer
Requirements for the patient
To 99 Years
All Gender
Medical requirements
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy